Cargando…

Prognostic Influence of the Time Interval between Surgery and Chemotherapy in Epithelial Ovarian Cancer

The influence of time to chemotherapy (TTC) on recurrence and survival among epithelial ovarian cancer (EOC) patients still remains unknown. This single center retrospective cohort study was conducted on 489 EOC patients who underwent surgery followed by taxane- plus platinum-based chemotherapy in t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Xiao-Dong, Liu, Yi, Gong, Ting-Ting, Guo, Jing-Yi, Wang, Ya-Nan, Wang, Ling, Wu, Qi-Jun, Jiao, Yi-Sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6277625/ https://www.ncbi.nlm.nih.gov/pubmed/30519317 http://dx.doi.org/10.7150/jca.27409

Ejemplares similares

Prognostic value of preoperative hyponatremia in patients with epithelial ovarian cancer
por: Guo, Jing-Yi, et al.
Publicado: (2019)

ABO Blood Type Has No Impact on Survival in Patients with Epithelial Ovarian Cancer
por: Wang, Ling, et al.
Publicado: (2018)

Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
por: Liu, Xingyu, et al.
Publicado: (2023)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer
por: Lin, Hao, et al.
Publicado: (2021)

Prognostic influence of an early time to chemotherapy following primary cytoreductive surgery for advanced epithelial ovarian cancer
por: Eisenkop, Scott M., et al.
Publicado: (2022)

Comorbidity and survival among women with ovarian cancer: evidence from prospective studies
por: Jiao, Yi-Sheng, et al.
Publicado: (2015)

Neoadjuvant chemotherapy followed by interval debulking surgery for advanced epithelial ovarian cancer: GOTIC-019 study
por: Nagao, Shoji, et al.
Publicado: (2023)

Impact of the time interval between primary or interval surgery and adjuvant chemotherapy in ovarian cancer patients
por: Farolfi, Alberto, et al.
Publicado: (2023)

The added value of CA125 normalization before interval debulking surgery to the chemotherapy response score for the prognostication of ovarian cancer patients receiving neoadjuvant chemotherapy for advanced disease
por: Liang, Wei-feng, et al.
Publicado: (2021)

Neoadjuvant chemotherapy for Patients with advanced epithelial ovarian cancer: A Meta-Analysis
por: Zeng, Long-Jia, et al.
Publicado: (2016)

Impact of the Time Interval Between Primary Debulking Surgery and Start of Adjuvant Chemotherapy in Advanced Epithelial Ovarian Cancer [Corrigendum]
Publicado: (2021)

Prognostic Factors for Advanced Epithelial Ovarian Cancer Following Primary Cytoreductive Surgery or Neoadjuvant Chemotherapy
por: Nantasupha, Chalaithorn, et al.
Publicado: (2022)

Choosing the right timing for interval debulking surgery and perioperative chemotherapy may improve the prognosis of advanced epithelial ovarian cancer: a retrospective study
por: Wang, Dengfeng, et al.
Publicado: (2021)

Prognostic Value of Residual Disease after Interval Debulking Surgery for FIGO Stage IIIC and IV Epithelial Ovarian Cancer
por: Rutten, Marianne J., et al.
Publicado: (2015)

miR-206 as a prognostic and sensitivity biomarker for platinum chemotherapy in epithelial ovarian cancer
por: Yu, Xiaotang, et al.
Publicado: (2020)

Impact of the Time Interval from Neoadjuvant Chemotherapy to Surgery in Primary Ovarian, Tubal, and Peritoneal Cancer Patients
por: Chen, Ming, et al.
Publicado: (2018)

Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer
por: Morton, Molly, et al.
Publicado: (2021)

Characteristics and survival of ovarian cancer patients treated with neoadjuvant chemotherapy but not undergoing interval debulking surgery
por: Liu, Ying L., et al.
Publicado: (2019)

The effects of neoadjuvant chemotherapy and interval debulking surgery on body composition in patients with ovarian cancer
por: Vitarello, John, et al.
Publicado: (2021)

Treatment strategies for patients with advanced ovarian cancer undergoing neoadjuvant chemotherapy: interval debulking surgery or additional chemotherapy?
por: Yoneoka, Yutaka, et al.
Publicado: (2019)

The clinicopathological significance of miR-1307 in chemotherapy resistant epithelial ovarian cancer
por: Zhou, Yingying, et al.
Publicado: (2015)

Chemotherapeutic Regimens and Chemotherapy-Free Intervals Influence the Survival of Patients with Recurrent Advanced Epithelial Ovarian Carcinoma: A Retrospective Population-Based Study
por: Huang, Hsin-Ying, et al.
Publicado: (2021)

Optimal Time Interval between Neoadjuvant Platinum-Based Chemotherapy and Interval Debulking Surgery in High-Grade Serous Ovarian Cancer
por: Andrikopoulou, Angeliki, et al.
Publicado: (2023)

The prognostic effect of residual tumor for advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy or primary debulking surgery
por: Yang, Shi‐Ping, et al.
Publicado: (2022)

Prognostic significance of MyD88 expression by human epithelial ovarian carcinoma cells
por: Zhu, Yi, et al.
Publicado: (2012)

Postoperative chemotherapy had no prognostic effect on early‐staged young ovarian cancer with unilateral resection
por: Zhang, Xiaofei, et al.
Publicado: (2018)

The prognostic significance of human ovarian aging-related signature in breast cancer after surgery: A multicohort study
por: Hua, Xin, et al.
Publicado: (2023)

Dermatomyositis as presenting feature of ovarian cancer, treated with neo-adjuvant chemotherapy and interval debulking surgery()
por: Christie, Alan, et al.
Publicado: (2013)

Rethinking Radical Surgery in Interval Debulking Surgery for Advanced-Stage Ovarian Cancer Patients Undergoing Neoadjuvant Chemotherapy
por: Lee, Yong Jae, et al.
Publicado: (2020)

Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer
por: Chen, Wei-Chun, et al.
Publicado: (2022)

Thrombin promotes epithelial ovarian cancer cell invasion by inducing epithelial-mesenchymal transition
por: Zhong, Yi-Cun, et al.
Publicado: (2013)

Residual tumor and primary debulking surgery vs interval debulking surgery in stage IV epithelial ovarian cancer
por: Sørensen, Sarah Mejer, et al.
Publicado: (2022)

The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies
por: Qin, Meng, et al.
Publicado: (2017)

Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced‐stage ovarian cancer
por: Huang, Chueh‐Yi, et al.
Publicado: (2020)

Subsequent Development of Epithelial Ovarian Cancer After Ovarian Surgery for Benign Ovarian Tumor: A Population-Based Cohort Study
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Pre-diagnosis Dietary One-Carbon Metabolism Micronutrients Consumption and Ovarian Cancer Survival: A Prospective Cohort Study
por: Xu, He-Li, et al.
Publicado: (2022)

Interval between secondary cytoreductive surgery and adjuvant chemotherapy is not associated with survivals in patients with recurrent ovarian cancer
por: Jeong, Soo Young, et al.
Publicado: (2019)

Influence of lymphadenectomy on survival and recurrence in patients with early-stage epithelial ovarian cancer: a meta-analysis
por: Yang, Chenchen, et al.
Publicado: (2023)

Application of machine learning in prediction of Chemotherapy resistant of Ovarian Cancer based on Gut Microbiota
por: Gong, Ting-Ting, et al.
Publicado: (2021)

Evaluation of Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Stage III Epithelial Ovarian Cancer
por: Lei, Ziying, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_4qffeo9hm0i091qh9kaljueedi